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ABSTRACT
PTH metabolism is complex and the circulating forms include the intact
1-84 molecule as well as several carboxyl-terminal fragments. The first
generation of PTH assays included several types of competitive assays,
with specificities that spanned carboxyl, mid-region and amino-terminal
portions of the molecule. The limitations of these assays and the method-
ological evolution led to the description of 2nd generation non-compet-
itive immunometric assays for PTH in the late 80’s, based on the recogni-
tion of the PTH molecule by two different antibodies, one directed
against de amino-terminal and other against the carboxyl-terminal seg-
ments. The observation that in some circumstances “long” carboxyl-ter-
minal segments were also measured by 2nd generation assays led to the
development of 3rd generation assays based on amino-terminal specific
antibodies that are specific for the first amino acids, measuring only the
molecular forms that activate PTH1R. The practical and cost-benefit
advantages of these assays are still debatable. The recent observation
that carboxyl-terminal fragments of PTH have biological activity via a dis-
tinct receptor than PTH1R, points to the future need of more than one
assay in order to evaluate parathyroid hormone function. (Arq Bras
Endocrinol Metab 2006;50/4:621-627)
Keywords: Parathyroid hormone assay; Radioimmunoassay; Immuno-
metric assays; Circulating forms of parathyroid hormone
RESUMO
Evolução dos Ensaios para Paratormônio.
O metabolismo do PTH e complexo e as formas circulantes incluem o
PTH 1-84, assim como fragmentos C-terminal. A primeira geração de
ensaios para o PTH incluía vários ensaios competitivos com especifici-
dades para as regiões carboxi, meio da molécula e amino-terminal. A
limitação destes ensaios e a evolução metodológica, levaram ao
desenvolvimento dos ensaios não competitivos de 2ª. geração no final
dos anos 80, baseados no reconhecimento por dois anticorpos dife-
rentes, contra a porção amino e carboxi-terminal respectivamente. A
observação que em algumas circunstâncias segmentos carboxitermi-
nais longos também eram detectados, levou ao desenvolvimento dos
ensaios de 3ª. geração, baseados em anticorpos específicos para a
porção aminoterminal com maior especificidade para os primeiros
aminoácidos, e assim mensurando apenas a forma molecular que ativa
o PTH1R. As vantagens práticas e o custo-benefício deste ensaio ainda
e motivo de debate. A observação recente de que fragmentos car-
boxiterminais têm atividade biológica via receptor distinto, aponta para
a necessidade futura de mais de um ensaio para avaliar a função do
paratormônio. (Arq Bras Endocrinol Metab 2006;50/4:621-627)
Descritores: Paratormônio; Radioimunoensaio; Ensaio imunométrico; For-
mas circulantes do paratormônio
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PARATHYROID HORMONE (PTH) is a linear peptide of84 amino acids, produced in the parathyroid glands,
that plays a critical role as a systemic regulator of calci-
um, phosphate and vitamin D metabolites concentra-
tion in blood. It is also a major player in the regulation
of cellular activity in bone. Classical biological activities
of PTH are mediated by the PTH1R receptors present
in several tissues and the amino-terminal region of the
molecule contains the sequence necessary to active
PTH1R. Yet PTH present in the circulation is very het-
erogeneous, and this heterogeneity is the consequence
of a complex metabolism that initiates in the secretory
granule of the parathyroid cell and continues in periph-
eral tissues, mainly in the liver and the kidneys (1,2).
The result of the complex metabolism and regulation is
a very heterogeneous pool of “PTH peptides” in circu-
lation not only in normal conditions, but mainly in pri-
mary and secondary hyperparathyroidism, specially
those patients with renal insufficiency. Circulating forms
that are biologically active via PTH1R have very short
half-lives, and the so-called middle-region and carboxyl-
terminal fragments, metabolized mainly via glomerular
filtration, have longer half-lives (3).
Recent publications demonstrating the exis-
tence and importance of carboxyl-terminal PTH
receptors have not only brought more complexity to
the understanding of PTH physiology, but also to the
interpretation of PTH assay results (4-6). The correct
definition of what forms are recognized is of para-
mount importance to the correct interpretation of
assay results.
The evolution of PTH measurement since the
description of the first assay by Berson et al. in 1963 (7)
took place in parallel to the knowledge about PTH phys-
iology and general immunoassay assay methodology.
Better methods provided more information that stimu-
lated the development of new methods with higher sen-
sitivity and specificity. The evolution of the knowledge in
this area if far from ended, and we can foresee new and
important information being unveiled in the near future.
For the sake of simplicity we divided the PTH
assays in methods of the first phase of evolution,
including basically competitive assays (1st generation
assays), and methods of the second phase, basically
non-competitive assays (2nd and 3rd generation assays).
FIRST PHASE: COMPETITIVE ASSAYS
Berson et al., in 1963, described the first radioim-
munoassay for human PTH (7), initiating a new era in
the diagnosis of parathyroid diseases. Other radioim-
munoassays followed, all of them using bovine (or
porcine) PTH for labeling and antibody production.
These heterologous assays were based on the cross-
reactivity of the antibody, generated against PTH
extracted from animal glands, with human PTH.
Assays with very acceptable characteristics and clinical
correlation were described (8,9). The problem with
these assays was mainly two fold: in the first place their
use was restricted due to the rarity of the antibodies,
additionally their specificity was ill defined and vari-
able, depending on preparation used for labeling and
on the standard employed (10). Based on these diffi-
culties and on the evolution of knowledge on PTH
structure and peptide synthesis, two new approaches
were used to develop new antibodies against human
PTH: the use of human parathyroid adenoma extracts
and synthetic peptides. Fischer et al. (11) were the first
to describe the production of antibodies against PTH
synthetic peptides, and the preparation of antisera
against peptides obtained from human adenoma
extracts was first described by Manning et al. (12).
Synthetic sequences with a tyrosine added were used
for iodine labeling, resulting in more stable, specific
and reproductive assays.
The better definition of the specificity of the
assays allowed their classification in three general
groups: carboxyl, mid-region and amino-terminal spe-
cific, depending on the region of the molecule recog-
nized by the antibody-tracer pair. The first to be
described and the most common assays were the car-
boxyl-terminal specific, a practical consequence of the
fact that the carboxyl-terminal portion of the molecule
is more antigenic and the adenoma extracts used for
immunization contained more carboxyl-terminal frag-
ments (13). Some assays were well characterized and
clinically useful, the main problem being their limited
use in patients with decrease in glomerular filtration due
to the retention of these fragments in this condition
(14). The so called “mid-region” specific assays used
PTH fragments representing the sequence between
amino acids 44 to 68 as tracer, recognizing intact PTH
and also some carboxyl-terminal fragments of unknown
composition (15). Apparently they presented better
clinical correlation than the carboxyl-terminal assays,
but the limitations can be defined as similar.
Potts et al. (16), in 1971, described that the
synthetic 1-34 fragment was biologically active and
equipotent to the complete 1-84 sequence concerning
the classical actions of PTH. Based on this knowledge,
at less theoretically, the better assays should be amino-
terminal specific, since they recognize the portion of
the molecule known to have the classical PTH action.
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An amino-terminal specific assay was described by
Desplan et al. in 1977 (17), and soon other groups
also published similar assays (18,19). We had a long
experience with the development and use of an amino-
terminal specific assay based on egg yolk-extracted
antibodies produced in chicken immunized against
synthetic hPTH-(1-34) (20). We also compared this
assay with a carboxyl-terminal specific assay in the
diagnosis of primary hyperparathyroidism (21), as well
as in the evaluation of parathyroid function in patients
with renal insufficiency (14,22). Since the circulation
of amino-terminal fragments is negligible (22), these
amino-terminal specific assays measured mainly intact
hormone, supposedly bioactive. Nonetheless, the
amino-terminal radioimmunoassays also had some
basic limitations, mainly the high sensitivity required.
We should never forget that the measurement of the
intact form of PTH is a methodological challenge
because besides the heterogeneity of the circulating
hormone, its concentration is extremely low, in the
order of tents of pmol/L. The intrinsic limitations of
the competitive immunoassay design restricted further
development, and the rarity of good antisera and diffi-
culties in attaining the required specific activity of the
tracer, confined the amino-terminal specific assays to a
few reference laboratories. In table 1 we summarize
the different competitive assays developed for PTH
measurement.
SECOND PHASE: NON-COMPETITIVE ASSAYS
In the late 80’s, with the description of the first
immunometric assays for the measurement of PTH in
serum or plasma (non-competitive, “sandwich” assays,
or 2nd generation assays), almost all the difficulties of
interpretation, availability and validation, common to
the large variety of different competitive immunoas-
says (1st generation), were considered overcome (23).
Immunometric assays are based on two distinct anti-
bodies that recognize two different epitopes, one
amino-terminal and other carboxyl-terminal and, at
least theoretically, measured only “intact” (1-84)-
PTH molecule. The meaning of “intact” PTH includ-
ed the notion of bioactive PTH, or PTH that was
capable of binding and activating PTH1R. Despite a
remarkable improvement in diagnostic sensitivity,
studies began to show that in some clinical circum-
stances, mainly in patients with renal insufficiency, the
assays appeared to be measuring something more than
just “intact” (1-84)-PTH (24). New investigations
provided data suggesting that other molecular forms,
specifically N-terminally truncated PTH-derived frag-
ments (e.g. PTH 7-84), were also measured by the
available immunometric assays (25,26).
The development of a new generation (3rd) of
immunometric assays, with the amino terminal specif-
ic antibody directed to the first four amino-terminal
amino acids (fundamental for activation of the
PTH1R), opened a new chapter in this field of study.
It is logical to infer that an assay that claims to mea-
sure “intact” PTH should measure what it states it
does. The problem is that there is controversy in the
real practical superiority of these new assays.
It is now known that 2nd generation PTH assays
measure more than PTH-(1-84) (figure 1), but how
much more can vary between different assays. Despite
a general agreement and uniformity of the normal
range expected for these assays, slight differences were
observed in their cross-reactivity with the 7-84 pep-
tide, probably related to differences in the specificity of
the amino terminal specific antibodies used (27).
Some assays use polyclonal affinity-purified antibodies
(obtained in goat, sheep or chicken), other use mono-
clonal antibodies (23,28). But is the 7-84 sequence
the only “long carboxyl-terminal” fragment present?
Almost certainly not, and the cross-reactivity of the
different assays with the various fragments can account
for the slight differences in the “intact” PTH values
obtained with the available commercial assays. Third
Table 1. General classification of competitive PTH assays.
1 Assays using antibodies generated against bovine (or porcine) PTH extracted from
glands and the same preparation labeled with Iodine as tracer.
2 Assays using antibodies generated against human PTH adenoma extracts and bovine
or human labeled PTH preparations as tracer.
3 Assays using antibodies generated against human or bovine PTH preparations and
synthetic carboxyl, mid-region or amino-terminal sequences.
4 Assays using antibodies generated against synthetic human PTH peptides (carboxyl,
mid-region and amino-terminal) and the corresponding thyrosilated synthetic peptide
labeled with Iodine as tracer.
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generation assays do not suffer from this incertitude, at
least in what concerns the amino-terminal antibody
specificity. Only PTH forms including the first 1-4
amino acids are recognized (figure 1). The epitopes
recognized by the other antibody, the carboxyl-termi-
nal specific, can also potentially lead to slight differ-
ences between methods.
2nd x 3rd Generation Assays in the Diagnosis of
Primary Hyperparathyroidism (PHP)
In typical patients with PHP it is difficult to image
how a more specific, 3rd generation assay for PTH
would improve the diagnostic accuracy, since most of
the patients have normal renal function. Maybe in bor-
derline cases, where the clinical and laboratory data are
dubious, a more specific assay would help. Clear evi-
dence that the 3rd generation assay improves diagnos-
tic sensitivity and specificity is still disputable (29-31).
One point not to be neglected is the huge clinical
experience accumulated with the 2nd generation assays
during more than 15 years of extensive use. A real con-
clusion about the superiority of the 3rd generation
assays must include a solid definition of the normal
range and extensive clinical experience. Concerning
the intra-operative PTH measurement, 3rd generation
assays also have the potential of being more useful,
since the half-life of (1-84)-PTH is shorter than the
half-life of the potential nt-(1-84)-PTH fragments
present. That would allow an earlier identification of a
significant fall in PTH levels, but this diagnostic
improvement also remains to be documented. One last
point that must be analyzed is the cost-benefit of the
information obtained by the two assays, since the 3rd
generation assays tend to be more expensive and not
widely available.
2nd x 3rd Generation Assays in the Diagnosis of
Hyperparathyroidism Secondary to Renal 
Insufficiency (SHP)
Since the introduction of 2nd generation PTH assays,
the levels of PTH in patients with renal insufficiency
were found to be higher than the clinical, and most
importantly, the bone histomorphometric presenta-
tion, would predict. The seminal work of Quarles et al.
in 1992 (24) was the first to clearly demonstrate this
fact and since then, values two to three times the
upper limit of normality where considered as reflecting
a normal PTH function in patients with renal insuffi-
ciency. The first, and simplest answer to this observa-
tion was that there was a resistance to PTH action in
these patients, which proved to be at least partially
true. Meanwhile Brossard and colleagues, in 1996
(32), were the first to show that there was an accumu-
lation of other non-(1-84) forms in ESRD patients
that were measured by “intact” PTH assays (2nd gen-
eration) as well as the true biologically active (1-84)-
PTH. In figure 2 we depict our experience, using our
2nd generation assay (28) in samples from patients with
PHP and samples from patients with SHP, submitted
to HPLC fractionation. The second peak corresponds
Figure 1. Schematic representation of 2nd and 3rd generation immunometric assays for PTH. The
carboxyl-terminal antibody is common to both assays; amino-terminal specific antibody of 2nd




Antibody (2nd Generation Assay)
Antibody specific for the fist 6 aa
(3rd Generation Assay)
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to (1-84)-PTH forms, and the first to lower molecular
weight forms, supposedly (7-84)-PTH. The peak
exists in both groups of patients, but is significantly
more important in the patients with renal insufficien-
cy. Besides the quite unpredictable factor of how
much of the PTH measured by a 2nd generation assay
corresponds to PTH that binds and activates PTH1R,
there is the variable of the transient effects of the ther-
apy imposed to ESRD patients. The use of phosphate
binders, calcium and vitamin D supplementation, dial-
ysis bath calcium concentration, aluminum intoxica-
tion, all induce PTH function short- and long-term
modifications that can have an immediate effect in the
PTH serum levels but would only affect bone biopsy
findings if they persist for a long time.
The introduction of 3rd generation assays that,
by definition, measure only (1-84)-PTH, brought the
possibility that in patients with secondary hyper-
parathyroidism due to renal insufficiency we would
obtain results with a more real meaning. In these
patients, the retention of long carboxyl-terminal frag-
ments potentially interferes with the results of 2nd gen-
eration assays. A simplistic approach would be to con-
sider that since these fragments don’t interfere in 3rd
generation assays, the results obtained with this latter
type of assay could be interpreted as a real portrait of
the PTH function status. Some recent publications
showed that this could be the case, in special if you
measure PTH using both 2nd and 3rd generation assays
and use the difference between results, the so-called
nt-(1-84)-PTH, to calculate a relationship between
the PTH1R active ((1-84)-PTH) and non-active (nt-
(1-84)-PTH), or “7-84” forms (33,34).
In spite of all logic behind this approach, other
publications, from several reference centers showed
that the correlation between bone status and PTH
measurements in patients with ESRD was similar using
3rd or 2nd generation assays (35,36). The same obser-
vation stands for the relationship between the “1-
84/7-84” relationship. Furthermore, the correlation
between PTH values obtained with 2nd and 3rd gener-
ation assays is excellent, even in patients with ESRD.
To try to understand why the logic does not seem to
work two aspects must be taken into account: first that
the nt-(1-84)-PTH that we are measuring (by sub-
tracting 2nd generation from 3rd generation assay val-
ues) does not include a significant part of the C-termi-
nal receptor binding peptides, not recognized by the
2nd generation assays. The second aspect is that differ-
ent factors, not directly related to PTH levels, con-
tribute, in variable degree, to the PTH resistance sta-
tus seen in patients with ESRD.
One important point concerning the physiologi-
cal role of the nt-(1-84)-PTH forms are the recent pub-
lications by Divieti et al. (4,5) showing that this forms
have biological action that is independent of activation
or blocking of PTH1R. More importantly, a putative C-
PTH receptor can be activated by forms shorter than
(7-84)-PTH. These include (24-84)-PTH and even,
albeit with less affinity, (39-84)-PTH. These findings
can have important implications on the interpretation of
the 2nd/3rd generation PTH measurement ratios in
ESRD patients, since the 2nd generation assays are usu-
ally based on antibodies that recognize epitopes in the
amino terminal region that may not be present in some
of the “shorter” nt-(1-84)-PTH fragments. In other
words, in this specific context, an immunometric assay
using an antibody recognizing a different epitope
Figure 2. Elution profiles obtained by HPLC for serum from a patient with primary hyperparathyroidism (A) and hyperparathy-
roidism secondary to chronic renal failure (B). nt-(1-84)-PTH= n-truncated (1-84)-PTH fragments.
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(including amino acids 30 to 40 for example) could
potentially provide more information than the tradi-
tional 2nd generation assays. The notion that ionized
calcium concentration contributes to the modulation of
circulating PTH immunoheterogeneity adds additional
complexity to the interpretation of PTH measurement
in ESRD patients (2). Metabolism of carboxyl-terminal
fragments in these patients is highly compromised by
the declining glomerular filtration rates.
CONCLUSIONS
The evolution of PTH assays has been remarkable, but
as usually happens, also our knowledge on the complex
metabolism of this hormone evolved in parallel. The
notion that PTH is a “polyhormone” was raised for the
first time by Mallette (37) and is acquiring even more
plausibility by the recent description of several different
forms of circulating PTH (38-40). These observations,
together with the evidence of the presence of a car-
boxyl-terminal specific receptor (4-6), point to a more
complex scenery where different clinical conditions will
require different assays in order to define the complex
situation of parathyroid physiology. For the definition
of primary hyperparathyroidism, where we are con-
cerned with the PTH forms that act on the PTH1R
(classical pathway), the available 2nd generation assays
are quite satisfactory (41), and the 3rd generation assays
may have advantages only in special conditions. In the
presence of renal insufficiency 2nd generation assays are
informative for most situations, being the use of 3rd
generation assays dependent on their availability and
validation of their cost-benefit.
Parathyroid function is complex and subject to
several different influences. Maintenance of serum cal-
cium in a very strict normal level is only one of the
physiological functions of this hormone. We think that
for the evaluation of the complex PTH influence in
bone and mineral metabolism, different assays recog-
nizing “long” carboxyl-terminal forms will be required
in some situations, complementing the information
obtained by 2nd/3rd generations assays.
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